Patterns of Antibacterial Therapy of Community-Acquired Pneumonia in Hospitalized Adults in Different Regions of Russia: Lessons from Multicentre Pharmacoepidemiology Study | CMAC

Patterns of Antibacterial Therapy of Community-Acquired Pneumonia in Hospitalized Adults in Different Regions of Russia: Lessons from Multicentre Pharmacoepidemiology Study

Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(1):66-78

​ Rachina S.A., Kozlov R.S., Shal E.P., Nedorozenyuk I.V., Leshchenko I.V., Bochanova E.N., Kuzin V.B., Mozhina L.N., Gestkov A.V., Oskina A.A., Reshetko O.V., Burdinskaya Yu.V., Ortenberg E.A., Suleymanov S.Sh., Ignatova G.L., Palyutin Sh.H., Ustyuganin I.V.
community-acquired pneumonia in adults antibacterial therapy multicentre pharmacoepidemiology studies
Section
Pharmacoepidemiology
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(1):66-78

Abstract

The aim of the study was to examine the patterns of systemic antibiotic (AB) use in adults with communityacquired pneumonia (CAP) in multi-word hospitals of different regions of Russia and assess the adherence of antibacterial therapy to the Russian national guidelines of CAP management. A total of 3798 clinical charts of patients with confirmed diagnosis of CAP (mean age 49,5±19,9 years old, 58% males, 29,5% – with severe pneumonia) in 29 multiward hospitals of 13 cities hospitalized in 2005–2006 were included into the study. Antibiotics were prescribed to 99,8% of patients. Cefotaxim, ampicillin and ceftriaxone were the most commonly used AB for non-severe CAP, ampicillin, cefotaxim and ceftriaxone – for severe cases (prescribed in 28,3, 21,2, 17,3 and 26%, 18,3%, 14,8% of cases, respectively). Combinations of AB as the first line therapy were given to 15,7% of patients with non-severe and 33,7% – with severe CAP. Prescribing of AB in accordance with the national guidelines was observed in 72,3% and 14,7% of patients; switching from IV to oral AB in compliance with the existing criteria – in 18% of patients, mean length of antibacterial therapy was 13,2±5,6 days. Quality of AB therapy in hospitalized adults with CAP varied significantly between sites. High rate of inadequate AB choice in case of severe CAP, low performance of step-down AB therapy and inaccurate use of AB combinations were the most critical problems.

  • 1. Battleman D.S., Callahan M., Thaler H.T. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with communityacquired pneumonia: link between quality of care and resource utilization. Arch Intern Med. 2002;162: 682-8.
  • 2. Houck P.M., Bratzler D.W., Nsa W., et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004; 164: 637-44.
  • 3. Mortensen E.M., Restrepo M., Anzueto A., Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726-31.
  • 4. Dean N.C., Silver M.P., Bateman K.A., et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110:451-7.
  • 5. Boada Senciales F., Moreno Arrebola E., Buñuel Alvarez J.C., Vila Pablos C. Impact of clinical practice guides on the cost of caring for community acquired pneumonia. An Pediatr (Barc). 2008; 69(2):154-8.
  • 6. Blasi F., Iori I., Bulfoni A., et al. Can CAP guideline adherence improve patient outcome in internal medicine departments? Eur Respir J. 2008; 32(4):902-10.
  • 7. Reyes Calzada S., Martínez Tomas R., Cremades Romero M.J., et al. Empiric treatment in hospitalized communityacquired pneumonia. Impact on mortality, length of stay and re-admission. Respir Med. 2007; 101(9):1909-15.
  • 8. Orrick J.J., Segal R., Johns T.E., et al. Resource use and cost of care for patients hospitalised with community acquired pneumonia: impact of adherence to infectious diseases society of america guidelines. Pharmacoeconomics 2004; 22(11):751-7.
  • 9. Niderman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
  • 10. Scott G., Scott H., Turley M., Baker M. Economic cost of community-acquired pneumonia in New Zealand adults. N Z Med J. 2004;117(1196): U933.
  • 11. Bauer T.T., Welte T., Ernen C., et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest. 2005;128(4): 2238-46.
  • 12. Mandell L.A., Wunderink R.G., Anzueto A, et al. IDSA/ ATS Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2): S27-72.
  • 13. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике у взрослых. М: Атмосфера, 2006.
  • 14. British Thoracic Society guidelines for the management of community-acquired pneumonia in adults – 2004 update. Available from: www.brit-thoracic.org.uk.
  • 15. Jackson M.L., Neuzil K.M., Thompson W.W., et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39: 1642-50.
  • 16. Страчунский Л.С., Козлов С.Н., Рачина С.А.. Фармакоэпидемиология: основные понятия и практическое применение. Клиническая фармакология и терапия 2001; 4: 4-7.
  • 17. Рачина С.А., Зайцев А.А. Фармакоэпидемиологическ ие исследования антибактериальных препаратов при внебольничных инфекциях дыхательных путей. В кн.: Синопальников А.И., Козлов Р.С.. Внебольничные инфекции дыхательных путей: диагностика и лечение. Руководство для врачей. М: ООО «Издательский дом «М-Вести», 2008; C. 254-71.
  • 18. Чучалин А.Г., Синопальников А.И., Яковлев С.В. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Пособие для врачей. Москва, 2003.
  • 19. Gleason P.P., Kapoor W.N., Stone R.A., et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278:32-9.
  • 20. Stahl J.E., Barza M., DesJaidin J., et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-80.
  • 21. Martinez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. CID 2003; 36:389-95.
  • 22. Lode H, Grossman C, Choudhri S, et al. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med 2003; 97(10):1134-42.
  • 23. Barlow G.D., Lamping D.L., Davey P.G., Nathwani D. Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians and policy-makers. Lancet Infect Dis 2003; 3:476-88.
  • 24. Metersky M.L. Community-acquired pneumonia: process of care studies. Curr Opin Infect Dis 2002; 15:169-74.
  • 25. Рачина С.А. Индикаторы качества ведения пациентов с внебольничной пневмонией. В кн.: Чучалин А.Г., Синопальников А.И., Страчунский Л.С.. Пневмония. М: МИА, 2006; C. 95-110.
  • 26. Лукашенко Е.П., Чикина С.Ю., Черняев А.Л. Ретроспективный анализ ведения больных внебольничной пневмоиней в стационаре. Проблемы клинической медицины 2008; 16 (4):35-40.
  • 27. Rhew D.C., Tu G.S., Ofman J., et al. Early switch and early discharge strategies in patients with communityacquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161:722-7.
  • 28. Halm E.A., Fine M.J., Marrie T.J., et al. Time to clinical stability in patients hospitalized with communityacquired pneumonia: implications for practice guidelines. JAMA 1998; 279:1452-7.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared